# DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Female
**Age Group:** 18 years and over
This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of HR+ DCIS (at least 50% ER or PR (from biopsy at diagnosis) with or without microinvasion - may have received endocrine therapy - see link to clinicaltrials.gov for complete Inclusion criteria

**Exclusion Criteria:**

- women who are pregnant or breast feeding - breast cancer is invasive - unable to swallow tablets or capsules - gastrointestinal conditions that would interfere with absorption of medication -- see link to clinical trials.gov for complete Exclusion criteria

## Conditions & Interventions

**Interventions:**
Drug: Anastrazole, Drug: Elacestrant, Drug: Exemestane, Drug: Letrozole, Drug: Tamoxifen, Drug: Testosterone + Anastrazole, Drug: Z-endoxifen
**Conditions:**
Cancer
**Keywords:**
Clinics and Surgery Center (CSC), breast cancer, DCIS

## More Information

**Description:** The trial offers women with ductal cell carcinoma in situ (DCIS) 6 months of neoadjuvant exposure to endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.
**Study Contact:** Jane Hui - jhui@umn.edu
**Principal Investigator:** Jane Hui
**Phase:** PHASE2
**IRB Number:** STUDY00022523